Table 2.
Proportion of patients with chronic spontaneous urticaria achieving complete or partial response on updosing omalizumab from 300 to 450 or 600 mg every 4 weeks
| Study | Updosed to 450 mg | Updosed to 600 mg | Efficacy parameter (UAS7/UCT) | Complete/partial response, % |
|---|---|---|---|---|
| Asher et al. | 9 | UAS7 ≤ 6 | 66.7 (n = 6)/22.2 (n = 2) | |
|
Kocatürk et al. Barcelona Istanbul |
17 | 11 | UCT ≥ 12 and UAS7 ≤ 6 | 64.3 (n = 18) |
| 11 | UCT ≥ 12 | 72.7 (n = 8) | ||
| Vadasz et al. | 78 | 64.1 (n = 50) | ||
| Curto-Barredo et al. | 79 | UAS7 ≤ 6 | 75.0 (n = 59)/25.0 (n = 20) | |
| Salman et al. | 13 | UCT ≥ 12 and UAS7 ≤ 6 | 46.2 (n = 6)/23.1 (n = 3) | |
| Aghdam et al. | 11 | 33 | UCT ≥ 12 and UAS7 ≤ 6 | 32.0 (n = 14)/30.0 (n = 13) |
UAS7 Urticaria Activity Score over 7 days; UCT, Urticaria Control Test